Advances in Bacteriophage Therapy against Relevant MultiDrug-Resistant Pathogens

Broncano-Lavado, Antonio; Santamaría-Corral, Guillermo; Esteban, Jaime; García-Quintanilla, Meritxell

doi:10.3390/antibiotics10060672

Open AccessReview

Advances in Bacteriophage Therapy against Relevant MultiDrug-Resistant Pathogens

by

Antonio Broncano-Lavado

^†

,

Guillermo Santamaría-Corral

^†

,

Jaime Esteban

and

Meritxell García-Quintanilla

^*

Department of Clinical Microbiology, IIS-Fundación Jiménez Díaz, Av. Reyes Católicos, 2, 28040 Madrid, Spain

^*

Author to whom correspondence should be addressed.

^†

These authors contributed equally to this work.

Antibiotics 2021, 10(6), 672; https://doi.org/10.3390/antibiotics10060672

Submission received: 7 May 2021 / Revised: 28 May 2021 / Accepted: 2 June 2021 / Published: 4 June 2021

(This article belongs to the Special Issue Benefits of Bacteriophages to Combat Antibiotic-Resistant Bacteria)

Download Review Reports Versions Notes

Abstract

The increase of multiresistance in bacteria and the shortage of new antibiotics in the market is becoming a major public health concern. The World Health Organization (WHO) has declared critical priority to develop new antimicrobials against three types of bacteria: carbapenem-resistant A. baumannii, carbapenem-resistant P. aeruginosa and carbapenem-resistant and ESBL-producing Enterobacteriaceae. Phage therapy is a promising alternative therapy with renewed research in Western countries. This field includes studies in vitro, in vivo, clinical trials and clinical cases of patients receiving phages as the last resource after failure of standard treatments due to multidrug resistance. Importantly, this alternative treatment has been shown to be more effective when administered in combination with antibiotics, including infections with biofilm formation. This review summarizes the most recent studies of this strategy in animal models, case reports and clinical trials to deal with infections caused by resistant A. baumannii, K. pneumoniae, E. coli, and P. aeruginosa strains, as well as discusses the main limitations of phage therapy.

Keywords: bacteriophage; alternative therapy; phage therapy; multiresistant; Acinetobacter baumannii; Klebsiella pneumoniae; Escherichia coli; Pseudomonas aeruginosa

Share and Cite

MDPI and ACS Style

Broncano-Lavado, A.; Santamaría-Corral, G.; Esteban, J.; García-Quintanilla, M. Advances in Bacteriophage Therapy against Relevant MultiDrug-Resistant Pathogens. Antibiotics 2021, 10, 672. https://doi.org/10.3390/antibiotics10060672

AMA Style

Broncano-Lavado A, Santamaría-Corral G, Esteban J, García-Quintanilla M. Advances in Bacteriophage Therapy against Relevant MultiDrug-Resistant Pathogens. Antibiotics. 2021; 10(6):672. https://doi.org/10.3390/antibiotics10060672

Chicago/Turabian Style

Broncano-Lavado, Antonio, Guillermo Santamaría-Corral, Jaime Esteban, and Meritxell García-Quintanilla. 2021. "Advances in Bacteriophage Therapy against Relevant MultiDrug-Resistant Pathogens" Antibiotics 10, no. 6: 672. https://doi.org/10.3390/antibiotics10060672

APA Style

Broncano-Lavado, A., Santamaría-Corral, G., Esteban, J., & García-Quintanilla, M. (2021). Advances in Bacteriophage Therapy against Relevant MultiDrug-Resistant Pathogens. Antibiotics, 10(6), 672. https://doi.org/10.3390/antibiotics10060672

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Menu

Advances in Bacteriophage Therapy against Relevant MultiDrug-Resistant Pathogens

Abstract

Share and Cite

Article Metrics

Article Access Statistics

Further Information

Guidelines

MDPI Initiatives

Follow MDPI